CD70 and renal cell carcinoma: Collectively, these findings demonstrate that AlloCAR70-NKT cells possess high yield and purity, stable phenotype, strong Th1 cytokine polarization, and potent CAR-dependent and -independent antitumor activity, supporting their promise as a universal, off-the-shelf cell therapy platform for CD70+ malignancies such as RCC.